Healio

Tremfya reduces psoriatic arthritis severity, progression of structural damage

Please provide your email address to receive an email when new articles are posted on . Tremfya is an interleukin-23 inhibitor being evaluated for the treatment of psoriatic arthritis.
KXAN

TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to significantly reduce both the signs and symptoms and the progression of structural damage in adults living with ...

TREMFYA ® demonstrated clinically meaningful and statistically significant efficacy in patients with active psoriatic arthritis at risk for structural damage in Phase 3b study Topline results ...
Morningstar

TREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen

TREMFYA® offers the flexibility of self-administration from the start of treatment, building on the prior approval of subcutaneous induction in Crohn's disease TREMFYA® achieved significant rates of ...
Hosted on MSN

TREMFYA: This Breakthrough Treatment Is Now Clinically Proven to Protect Joints in Active Psoriatic Arthritis

New long‑term clinical data show that TREMFYA® (guselkumab), an IL‑23 inhibitor, is the first treatment of its kind to demonstrate durable protection against joint damage in patients with active ...
Morningstar

TREMFYA® (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn's disease at two years

*The as observed analysis set included participants who entered the LTE, received ≥1 partial or complete study drug dose during the LTE, remained on treatment, and had data available at Week 96; ...